What do systematic reviews say?

Immunomodulatory drug maintenance therapy vs placebo/observation

Immunomodulatory drug maintenance therapy showed no clear difference in overall survival compared with placebo/observation (moderate certainty).

• Maintenance therapy for chronic lymphocytic leukaemia 2024 · Cochrane Headline outcomes only
  HR 0.91 [0.61, 1.35]
  3 studies · 461 participants
  Moderate

Thrombopoietin mimetics vs placebo

• Thrombopoietin mimetics for patients with myelodysplastic syndromes 2017 · Cochrane Headline outcomes only
  no estimate extracted
  2 studies · 282 participants
  GRADE not reported

G‐CSF vs placebo

It is very uncertain whether G‐CSF changes overall survival compared with placebo (very low certainty).

• Granulocyte and granulocyte‐macrophage colony stimulating factors for newly diagnosed patients with myelodysplastic… 2016 · Cochrane Headline outcomes only
  HR 0.8 [0.44, 1.46]
  1 study · 64 participants
  Very low

Low molecular weight heparin vs placebo or no treatment

The review found no eligible studies for this question.

• Interventions for prophylaxis of hepatic veno‐occlusive disease in people undergoing haematopoietic stem cell… 2015 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Glutamine vs placebo

The review found no eligible studies for this question.

• Interventions for prophylaxis of hepatic veno‐occlusive disease in people undergoing haematopoietic stem cell… 2015 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Ursodeoxycholic acid vs placebo or no treatment

Summary of findings: Ursodeoxycholic acid showed no clear difference in overall survival ( compared with placebo or no treatment (low certainty).

• Interventions for prophylaxis of hepatic veno‐occlusive disease in people undergoing haematopoietic stem cell… 2015 · Cochrane Headline outcomes only
  HR 0.83 [0.59, 1.18]
  3 studies · 474 participants
  Low

Eculizumab vs placebo

• Eculizumab for treating patients with paroxysmal nocturnal hemoglobinuria 2014 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 87 participants
  GRADE not reported

Ruxolitinib vs placebo

Ruxolitinib may leads to lower overall survival (number of deaths at compared with placebo (low certainty).

• Janus kinase‐1 and Janus kinase‐2 inhibitors for treating myelofibrosis 2015 · Cochrane Headline outcomes only
  HR 0.51 [0.27, 0.98]
  1 study · 309 participants
  Low